公开(公告)号：US20180002394A1

公开(公告)日：2018-01-04

申请号：US15695392

申请日：2017-09-05

申请人： Wake Forest University Health Sciences

发明人： Waldemar Debinski ,  Hetal Pandya ,  Denise Gibo

IPC分类号： C07K14/54 ,  C07K14/005 ,  C07K14/195 ,  C07K14/21 ,  C07K19/00 ,  A61K47/64 ,  G01N33/68 ,  C07K14/34 ,  G01N33/50 ,  G01N33/532 ,  A61K38/00

CPC分类号： C07K14/5437 ,  A61K38/00 ,  A61K47/642 ,  C07K14/005 ,  C07K14/195 ,  C07K14/21 ,  C07K14/34 ,  C07K19/00 ,  C07K2319/01 ,  C07K2319/09 ,  C07K2319/74 ,  G01N33/5008 ,  G01N33/5091 ,  G01N33/532 ,  G01N33/6869 ,  G01N2333/025 ,  G01N2333/195 ,  G01N2333/5437

摘要： A compound comprising, in combination: a cell surface binding ligand or internalizing factor, such as an IL-13Rα2 binding ligand; at least one effector molecule (e.g., one, two, three or more effector molecules); optionally but preferably, a cytosol localization element covalently coupled between said binding ligand and said at least one effector molecule; and a subcellular compartment localization signal element covalently coupled between said binding ligand and said at least one effector molecule (and preferably with said cytosol localization element between said binding ligand and said subcellular compartment localization signal element). Methods of using such compounds and formulations containing the same are also described.

公开(公告)号：US09771398B2

公开(公告)日：2017-09-26

申请号：US14598148

申请日：2015-01-15

申请人： Arbor Vita Corporation ,  Becton, Dickinson and Company

发明人： Stephen Lovell ,  Lydia Blank ,  Virginia Crews ,  Nancy Hasse ,  Peter Lu ,  Johannes Schweizer ,  John Mantlo

IPC分类号： C07K14/005 ,  C07K14/82 ,  G01N33/569 ,  C07K1/14 ,  C12N7/00

CPC分类号： C07K14/005 ,  C07K1/145 ,  C07K14/82 ,  C12N7/00 ,  C12N2710/20051 ,  G01N33/56983 ,  G01N2333/025

摘要： Methods for producing a protein extract from cells, such as cells containing viral proteins, are provided. In general terms, the methods involve: increasing the pH of the cells to a pH of at least about pH 10.0 to produce an intermediate composition, and then, in the presence of a non-ionic detergent, neutralizing the pH of the intermediate composition to produce the protein extract. Kits and compositions for practicing the subject methods are also provided.

公开(公告)号：US20170247457A1

公开(公告)日：2017-08-31

申请号：US15596468

申请日：2017-05-16

申请人： Biogen MA, Inc.

发明人： Ivan Lieberburg

IPC分类号： C07K16/28 ,  G01N33/68 ,  A61K38/21 ,  A61K49/00 ,  A61K39/395 ,  A61K45/06

CPC分类号： C07K16/2839 ,  A61K38/03 ,  A61K38/215 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61K49/0004 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K16/2842 ,  C07K2317/24 ,  G01N33/6893 ,  G01N33/6896 ,  G01N2333/025 ,  G01N2800/065 ,  G01N2800/285 ,  G01N2800/7095 ,  Y02A50/467

摘要： Natalizumab is a safe and efficacious treatment for inflammatory and autoimmune diseases, such as multiple sclerosis, Crohn's Disease, and rheumatoid arthritis. Rare occurrences of progressive multifocal leucoencephalopathy during treatment suggest the possibility that it may be related to natalizumab treatment. Monitoring for JCV and informing caregivers and patients about the manifestations of progressive multifocal leucoencephalopathy can improve the safety of natalizumab therapy.

公开(公告)号：US09683997B2

公开(公告)日：2017-06-20

申请号：US14973240

申请日：2015-12-17

申请人： Japan Health Sciences Foundation

发明人： Seiichiro Mori ,  Tadahito Kanda

IPC分类号： C12Q1/70 ,  G01N33/68 ,  C07K16/08 ,  G01N33/574 ,  A61K47/48 ,  G01N33/569 ,  A61K39/00

CPC分类号： G01N33/6854 ,  A61K47/6901 ,  A61K2039/505 ,  C07K16/084 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92 ,  C12Q1/70 ,  G01N33/56983 ,  G01N33/57411 ,  G01N2333/025 ,  G01N2800/26 ,  G01N2800/52

摘要： The present invention relates to the development of a monoclonal antibody which has binding activity to many high-risk types of HPV, etc. The present invention also provides a simple and high-throughput method for measuring cross-neutralizing antibody titers, which is used for assay of cross-neutralizing antibody against HPV in serum samples from subjects, etc. The method of the present invention for measuring cross-neutralizing antibody titers comprises the steps of: preparing a monoclonal antibody against a peptide having a specific amino acid sequence common to high-risk types of HPV; and assaying cross-neutralizing antibody using this monoclonal antibody.

公开(公告)号：US20170059568A1

公开(公告)日：2017-03-02

申请号：US15119793

申请日：2015-02-19

申请人： JANSSEN PHARMACEUTICA NV

发明人： Lieven Jozef Stuyver

IPC分类号： G01N33/569

CPC分类号： G01N33/56983 ,  G01N33/5091 ,  G01N2333/025 ,  G01N2800/285 ,  G01N2800/50

摘要： The invention relates to a method to predict the onset and/or development of PML in a patient or in an immunosuppressed patient by detection of JCV specific CTL's in blood of said patient using any of the ten (10) JCV amino acid sequences SEQ ID NO 1-10 separately or in combination with each other.

摘要翻译： 本发明涉及通过使用十（10）JCV氨基酸序列SEQ ID NO中的任何一个检测所述患者的血液中的JCV特异性CTL来预测患者或免疫抑制患者中PML发病和/或发展的方法 1-10分别或彼此组合。

公开(公告)号：US09568480B2

公开(公告)日：2017-02-14

申请号：US13989804

申请日：2011-11-30

申请人： Ralf Hilfrich

发明人： Ralf Hilfrich

IPC分类号： G01N33/558 ,  G01N33/68 ,  G01N33/569

CPC分类号： G01N33/56983 ,  G01N33/558 ,  G01N33/6854 ,  G01N2333/025

摘要： A rapid test for a qualitative and/or quantitative assay of antibodies present in body fluid against human papilloma viruses (HPV) includes mixing a specimen of body fluid with a reagent which essentially comprises a predetermined quantity of physiologically acting liquid and a predetermined quantity of at least one HPV-specific antigen. The mixture is fed to an analysis which utilizes a change that is at least one of measurable or perceivable by a user.

摘要翻译： 用于针对人乳头状瘤病毒（HPV）的体液中存在的抗体的定性和/或定量测定的快速测试包括将体液样本与基本上包含预定量的生理作用液体和预定量的 至少一种HPV特异性抗原。 将混合物供给到利用可由用户测量或可感知的至少一种的变化的分析。

公开(公告)号：US09568474B2

公开(公告)日：2017-02-14

申请号：US14335511

申请日：2014-07-18

申请人： Shuling Cheng

发明人： Shuling Cheng

IPC分类号： G01N33/569 ,  C07K16/08 ,  C12Q1/70 ,  G01N33/571

CPC分类号： G01N33/56983 ,  C07K16/084 ,  C12Q1/708 ,  G01N33/571 ,  G01N2333/025 ,  G01N2469/10

摘要： Embodiments of the invention provide methods, monoclonal antibodies, polyclonal antibodies, assays, and kits for detecting HPV infection and HPV related cancer diagnosis, including infection by various HPV genotypes, early and/or late stage HPV-associated or HPV-specific cancers. The anti-HPV antibodies are used in performing immunological assays on clinical samples. Various immunological assays and kits for detecting HPV infection, cervical cancer, other HPV related cancers, early stage precancerous lesions as well as late stage cancer progression are also provided.

摘要翻译： 本发明的实施方案提供用于检测HPV感染和HPV相关癌症诊断的方法，单克隆抗体，多克隆抗体，测定和试剂盒，包括各种HPV基因型，早期和/或晚期HPV相关或HPV特异性癌症的感染。 抗HPV抗体用于对临床样品进行免疫测定。 还提供了用于检测HPV感染，子宫颈癌，其他HPV相关癌症，早期癌前病变以及晚期癌症进展的各种免疫学测定和试剂盒。

公开(公告)号：US20170016919A1

公开(公告)日：2017-01-19

申请号：US15120573

申请日：2015-02-27

申请人： Biogen MA Inc.

发明人： Tatiana Plavina ,  John P. Carulli ,  Leonid Gorelik ,  Teresa Compton

IPC分类号： G01N33/68 ,  C12Q1/68

CPC分类号： G01N33/6896 ,  C12Q1/6883 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2333/025 ,  G01N2800/28 ,  G01N2800/50

摘要： The invention relates to methods of assessing a patient's risk of developing Progressive Multifocal Leukoencephalopathy (PML).

摘要翻译： 本发明涉及评估患者进展性多灶性脑白质病（PML）风险的方法。

公开(公告)号：US09547006B2

公开(公告)日：2017-01-17

申请号：US14455530

申请日：2014-08-08

申请人： Institut Pasteur ,  Institut National de la Sante et de la Recherche Medicale (INSERM) ,  Universite Paris Diderot—Paris 7 ,  Assistance-Publique Hopitaux de Paris

发明人： Marie-Lise Gougeon ,  Manuelle Viguier ,  Herve Bachelez ,  Nicolas Fazilleau

IPC分类号： A61K39/12 ,  C07K14/005 ,  C07K14/235 ,  C12N7/00 ,  C12Q1/04 ,  G01N33/569 ,  C12Q1/68 ,  A61K31/675 ,  A61K39/02 ,  A61K45/06 ,  A61N5/06 ,  C12Q1/70 ,  A61K39/00 ,  G01N33/50

CPC分类号： G01N33/56983 ,  A61K31/675 ,  A61K39/099 ,  A61K39/12 ,  A61K45/06 ,  A61K2039/545 ,  A61K2039/572 ,  A61K2039/575 ,  A61N5/0613 ,  C07K14/005 ,  C07K14/235 ,  C07K2319/55 ,  C12N7/00 ,  C12N2710/20034 ,  C12Q1/04 ,  C12Q1/6869 ,  C12Q1/708 ,  C12Q2600/158 ,  G01N33/5008 ,  G01N33/502 ,  G01N33/505 ,  G01N33/5091 ,  G01N33/56972 ,  G01N2333/025 ,  G01N2333/7051 ,  G01N2800/18 ,  G01N2800/52

摘要： A massive clonal expansion of activated CD8+ T-cells with increased frequency of HPV 16-specific CD8+ T-cells was discovered to be a characteristic of oral lichen planus (OLP), indicating a causal link between HPV infection and the dysimmune process. The invention relates to compositions and methods for the diagnosis and treatment of OLP patients.

摘要翻译： 发现HPV16特异性CD8 + T细胞频率增加的活化CD8 + T细胞的大量克隆扩增是口腔扁平苔藓（OLP）的特征，表明HPV感染与免疫应答过程之间存在因果关系。 本发明涉及用于诊断和治疗OLP患者的组合物和方法。

公开(公告)号：US20160305942A1

公开(公告)日：2016-10-20

申请号：US15196514

申请日：2016-06-29

申请人： UNIVERSITY OF MIAMI

发明人： Elizabeth Franzmann ,  Lutecia Pereira ,  Isildinha M. Reis ,  Robert C. Duncan

IPC分类号： G01N33/574

CPC分类号： G01N33/5743 ,  G01N33/57488 ,  G01N2333/025 ,  G01N2333/70585 ,  G01N2800/50

摘要： Methods and kits for diagnosing and determining prognosis of head and neck squamous cell carcinoma are described.